• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

炎症性肠病的联合生物治疗：来自三级医疗中心的经验。

Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center.

机构信息

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

出版信息

Clin Gastroenterol Hepatol. 2021 Mar;19(3):616-617. doi: 10.1016/j.cgh.2020.02.017. Epub 2020 Feb 14.

DOI:10.1016/j.cgh.2020.02.017
PMID:32068149
Abstract

The global incidence of inflammatory bowel disease (IBD) has increased considerably during the past few decades. IBDs, composed of Crohn's disease (CD) and ulcerative colitis (UC), are characterized by heterogeneous presentation and widely variable clinical course. The therapeutic goals are to induce and maintain remission. Despite the current treatments available, many patients do not achieve this goal.

摘要

在过去几十年中，炎症性肠病（IBD）的全球发病率显著上升。IBD 由克罗恩病（CD）和溃疡性结肠炎（UC）组成，其特征为表现多样且临床病程差异大。治疗目标是诱导并维持缓解。尽管目前有多种治疗方法，但许多患者无法实现这一目标。

相似文献

1
Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center.炎症性肠病的联合生物治疗：来自三级医疗中心的经验。
Clin Gastroenterol Hepatol. 2021 Mar;19(3):616-617. doi: 10.1016/j.cgh.2020.02.017. Epub 2020 Feb 14.
2
The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.沙特阿拉伯一家三级护理中心的炎症性肠病患者样本中生物治疗与非生物治疗的成本效益及健康相关生活质量
J Med Econ. 2020 Oct;23(10):1102-1110. doi: 10.1080/13696998.2020.1791889. Epub 2020 Jul 23.
3
Influence of Corticosteroid Use on Short- and Long-Term Outcomes of Biologic Therapy for Inflammatory Bowel Diseases.皮质类固醇使用对炎症性肠病生物治疗的短期和长期结局的影响。
Dig Dis Sci. 2022 Nov;67(11):5168-5176. doi: 10.1007/s10620-021-07361-z. Epub 2022 Jan 30.
4
Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center.在炎症性肠病患者中维得利珠单抗的长期疗效和安全性：来自一家三级转诊中心的真实世界经验。
J Dig Dis. 2019 May;20(5):235-242. doi: 10.1111/1751-2980.12748.
5
Current therapeutic approaches in inflammatory bowel disease.炎症性肠病的当前治疗方法。
Curr Pharm Des. 2010;16(33):3668-83. doi: 10.2174/138161210794079155.
6
Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.生物制剂在炎症性肠病患者中的使用模式及非持续性和转换的预测因素：一项全国性基于人群的研究。
Dig Dis Sci. 2020 May;65(5):1436-1444. doi: 10.1007/s10620-019-05867-1. Epub 2019 Nov 1.
7
Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.克罗恩病和溃疡性结肠炎。欧洲一项基于人群的起始队列研究中疾病第一年的发病率、病程及预后
Dan Med J. 2014 Jan;61(1):B4778.
8
Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease).优化炎症性肠病（溃疡性结肠炎和克罗恩病）的生物疗法。
Curr Gastroenterol Rep. 2009 Dec;11(6):504-8. doi: 10.1007/s11894-009-0076-5.
9
Medical Management of Inflammatory Bowel Disease.炎症性肠病的医学管理。
Surg Clin North Am. 2024 Jun;104(3):657-671. doi: 10.1016/j.suc.2023.12.005. Epub 2024 Jan 3.
10
Novel Small Molecules in IBD: Current State and Future Perspectives.新型小分子在炎症性肠病中的应用：现状与未来展望。
Cells. 2023 Jun 27;12(13):1730. doi: 10.3390/cells12131730.

引用本文的文献

1
Dual anti-cytokine biologic and/or targeted synthetic therapy combination in spondyloarthritis: a narrative review. Are we missing the opportunity for higher remission rates?脊柱关节炎中双重抗细胞因子生物制剂和/或靶向合成疗法联合应用：一项叙述性综述。我们是否错失了实现更高缓解率的机会？
Front Med (Lausanne). 2025 Jun 3;12:1576411. doi: 10.3389/fmed.2025.1576411. eCollection 2025.
2
Efficacy and safety of dual-targeted therapy for refractory inflammatory bowel disease: a retrospective case series from three tertiary general hospitals in China.双靶点疗法治疗难治性炎症性肠病的疗效与安全性：来自中国三家三级综合医院的回顾性病例系列研究
Front Med (Lausanne). 2025 May 12;12:1566828. doi: 10.3389/fmed.2025.1566828. eCollection 2025.
3
Discovery of Novel Tofacitinib-ADTOH Molecular Hybridization Derivatives for the Treatment of Ulcerative Colitis.
用于治疗溃疡性结肠炎的新型托法替布-ADTOH分子杂交衍生物的发现。
Antioxidants (Basel). 2025 Mar 8;14(3):325. doi: 10.3390/antiox14030325.
4
Comparative Effectiveness of Dual Biologic Therapy and Biologic Small-Molecule Therapy for Refractory Inflammatory Bowel Disease: A Retrospective Single-Center Study.双重生物疗法与生物小分子疗法治疗难治性炎症性肠病的疗效比较：一项回顾性单中心研究
Clin Transl Sci. 2025 Mar;18(3):e70198. doi: 10.1111/cts.70198.
5
Strengths, weaknesses, opportunities, and threats analysis of combination therapy for inflammatory bowel disease.炎症性肠病联合治疗的优势、劣势、机会和威胁分析
World J Gastroenterol. 2025 Mar 7;31(9):100607. doi: 10.3748/wjg.v31.i9.100607.
6
Dual Biologic Therapy Induces Remission in Refractory Crohn's Disease With Vedolizumab and Ustekinumab.维多珠单抗和优特克单抗联合生物疗法可诱导难治性克罗恩病缓解。
Crohns Colitis 360. 2024 Dec 17;7(1):otae080. doi: 10.1093/crocol/otae080. eCollection 2025 Jan.
7
Advancements in dual biologic therapy for inflammatory bowel diseases: efficacy, safety, and future directions.炎症性肠病双重生物疗法的进展：疗效、安全性及未来方向。
Therap Adv Gastroenterol. 2025 Jan 2;18:17562848241309871. doi: 10.1177/17562848241309871. eCollection 2025.
8
Efficacy and safety of dual-targeted therapy for inflammatory bowel disease: a retrospective multicenter study in China.炎症性肠病双靶点治疗的疗效与安全性：一项中国的回顾性多中心研究
Therap Adv Gastroenterol. 2025 Jan 2;18:17562848241307598. doi: 10.1177/17562848241307598. eCollection 2025.
9
Refractory Crohn's Disease: Perspectives, Unmet Needs and Innovations.难治性克罗恩病：观点、未满足的需求与创新
Clin Exp Gastroenterol. 2024 Oct 10;17:261-315. doi: 10.2147/CEG.S434014. eCollection 2024.
10
Current Treatments, Emerging Therapeutics, and Natural Remedies for Inflammatory Bowel Disease.炎症性肠病的当前治疗方法、新兴治疗方法和天然疗法。
Molecules. 2024 Aug 21;29(16):3954. doi: 10.3390/molecules29163954.